A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
BeOne Medicines
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Incyte Corporation
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
Verastem, Inc.
Pfizer
Tizona Therapeutics, Inc
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Pfizer
Fate Therapeutics
Eli Lilly and Company
Hummingbird Bioscience
Innovent Biologics (Suzhou) Co. Ltd.